Specificity of the basic side chains of Lys114, Lys125, and Arg129 of antithrombin in heparin binding.
The anticoagulant polysaccharide heparin binds and activates the plasma proteinase inhibitor antithrombin through a pentasaccharide sequence. Lys114, Lys125, and Arg129 are the three most important residues of the inhibitor for pentasaccharide binding. To elucidate to what extent another positively charged side chain can fulfill the role of each of these residues, we have mutated Lys114 and Lys125 to Arg and Arg129 to Lys. Lys114 could be reasonably well replaced with Arg with only an approximately 15-fold decrease in pentasaccharide affinity, in contrast to an approximately 10(5)-fold decrease caused by substitution with an noncharged amino acid of comparable size. However, a loss of approximately one ionic interaction on mutation to Arg indicates that the optimal configuration of the network of basic residues of antithrombin that together interact with the pentasaccharide requires a Lys in position 114. Replacement of Lys125 with Arg caused an even smaller, approximately 3-fold, decrease in pentasaccharide affinity, compared with that of approximately 400-fold caused by mutation to a neutral amino acid. An Arg in position 125 is thus essentially equivalent to the wild-type Lys in pentasaccharide binding. Substitution of Arg129 with Lys decreased the pentasaccharide affinity an appreciable approximately 100-fold, a loss approaching that of approximately 400-fold caused by substitution with a neutral amino acid. Arg is thus specifically required in position 129 for high-affinity pentasaccharide binding. This requirement is most likely due to the ability of Arg to interact with other residues of antithrombin, primarily, Glu414 and Thr44, in a manner that appropriately positions the Arg side chain for keeping the pentasaccharide anchored to the activated state of the inhibitor.
D019943:Amino Acid Substitution / Q000235:genetics; D000990:Antithrombin III / Q000737:chemistry* / Q000235:genetics / Q000302:isolation & purification; D001120:Arginine / Q000737:chemistry* / Q000235:genetics; D001665:Binding Sites / Q000235:genetics; D002414:Cations, Monovalent / Q000737:chemistry; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000737:chemistry*; D006801:Humans; D007700:Kinetics; D008239:Lysine / Q000737:chemistry* / Q000235:genetics; D016297:Mutagenesis, Site-Directed; D009844:Oligosaccharides / Q000737:chemistry; D012964:Sodium / Q000737:chemistry; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000378:metabolism
D002414:Cations, Monovalent; D065427:Factor Xa Inhibitors; D009844:Oligosaccharides; D000990:Antithrombin III; D006493:Heparin; D001120:Arginine; D012964:Sodium; D013917:Thrombin; D015951:Factor Xa; D008239:Lysine